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A B S T R A C T
Tuberculosis is one of the major public health concerns. This highly contagious disease aﬀects more than 10.4
million people, being a leading cause of morbidity by infection. Tuberculosis is diagnosed at the point-of-care by
the Ziehl-Neelsen sputum smear microscopy test. Ziehl-Neelsen is laborious, prone to human error and
infection risk, with a limit of detection of 104 cells/mL. In resource-poor nations, a more practical test, with
lower detection limit, is paramount. This work uses a magnetoresistive biosensor to detect BCG bacteria for
tuberculosis diagnosis. Herein we report: i) nanoparticle assembly method and speciﬁcity for tuberculosis
detection; ii) demonstration of proportionality between BCG cell concentration and magnetoresistive voltage
signal; iii) application of multiplicative signal correction for systematic eﬀects removal; iv) investigation of
calibration eﬀectiveness using chemometrics methods; and v) comparison with state-of-the-art point-of-care
tuberculosis biosensors.
Results present a clear correspondence between voltage signal and cell concentration. Multiplicative signal
correction removes baseline shifts within and between biochip sensors, allowing accurate and precise voltage
signal between diﬀerent biochips. The corrected signal was used for multivariate regression models, which
signiﬁcantly decreased the calibration standard error from 0.50 to 0.03 log10 (cells/mL). Results show that
Ziehl-Neelsen detection limits and below are achievable with the magnetoresistive biochip, when pre-processing
and chemometrics are used.
1. Introduction
Tuberculosis (TB) is a major global health concern and a destructive
disease, associated with high morbidity in 2015: 10.4 million people,
including 11% HIV-positive patients. Moreover, TB was reported as a
leading cause of mortality from an infectious agent, causing the death
of 1.4 million people (among 0.4 million HIV-positive) (WHO, 2016).
The impact of Mycobacterium tuberculosis (Mtb) bacterial infec-
tion is particularly signiﬁcant in resource-limited countries, which
represent more than 80% of global epidemics (WHO, 2015, 2016). In
these settings, direct Ziehl-Neelsen (ZN) sputum smear microscopy is
an important diagnostic technique, although the method is laborious
and prone to human error and to infection exposure (Yeo et al., 2009;
Matu and Juma, 2013; Creecy et al., 2015). ZN only identiﬁes TB
pulmonary cases in sputum samples, with a limit of detection (LOD) of
104 cells/mL (Arias-Bouda et al., 2000; Yeo et al., 2009; Creecy et al.,
2015). Therefore, active TB cases with lower number of cells, patients
with negative sputum results, children, HIV patients and extra-
pulmonary TB, need a diﬀerent diagnostic approach (Moreno-Pérez
et al., 2010; Parsons et al., 2011; Veigas et al., 2012; WHO, 2012).
Inexpensive point-of-care (POC) tests that can be used with blood or
urine, are extremely necessary (Arias-Bouda et al., 2000; Yeo et al.,
2009; Lange and Mori, 2010).
Immunoassays provide simple, inexpensive and rapid diagnosis,
including for people with negative sputum samples and immunosup-
pressed patients (Perkins and Cunningham, 2007; Lange and Mori,
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2010). Magnetoresistive (MR) biosensors can replace the enzymatic
detection label of immunosorbent assays (ELISA) with magnetic
nanoparticles (MNP), functionalized with speciﬁc antibodies (Abs)
and bioconjugated with bacterial cells (Fernandes et al., 2014;
Barroso et al., 2015). On the biochip surface, capture Abs bind speciﬁc
antigens on bacterial samples. Magnetically labelled cells are detected
by an array of spin-valve sensors, which are sensitive to small changes
in the magnetic ﬁeld of MNP (Germano et al., 2009; Martins et al.,
2009; Freitas et al., 2012; Giouroudi and Keplinger, 2013; Barroso
et al., 2015).
Fig. 1a presents the time course voltage signal variation of the MR-
biosensor, into three steps: A) Similarly to a common ELISA, the
surface is functionalized with speciﬁc capture Abs (right area of the
sensor) that bind matching antigens; control Abs are chemically
attached to the surface (left area) validating the speciﬁcity of the
platform; when no label is on the surface of the biosensor, a baseline
MR signal is registered (Vsensor); B) Then, the immunoassay follows a
sandwich format labelled by MNP functionalized with detection Abs
(anti-Mtb bio) and bioconjugated with target bacterial cells; when MNP
get near the biochip surface, a MR change is created by the magnetic
stray ﬁelds; this signal is detected by the sensors and a voltage drop is
observed; C) After 30 min of contact with the biochip surface, non-
bound MNP are washed out, and only the signal from labelled targets is
recorded (Vparticles).
For TB detection in blood, sputum or urine samples, which can
contain Mtb bacteria, it is necessary to remove all other components to
obtain a clean sample that can be injected into the MR-biochip. This
can be done by magnetic separation. Once magnetically-labelled Abs
are added to the sample, they speciﬁcally bind with mycobacteria,
which can be magnetically separated. Then, this puriﬁed solution is
injected into the biochip microﬂuidics. Magnetically functionalized
bacterial cells are captured by speciﬁc Abs on the MR-biochip surface.
The MR signal changes with time, as more cells attach to the surface
(step B - Fig. 1b). The rate of voltage change is proportional to cell
concentration. Once all MNP are bound to the biochip surface, there is
no longer a voltage variation. At this point, washing cycles are
necessary to remove non-bound MNP, only obtaining a voltage of the
bound mycobacteria. The mycobacterial cell concentration is after-
wards related to the diﬀerential between voltage at baseline (step A -
Fig. 1b) and the washing step (step C - Fig. 1b) (Martins et. al, 2009;
Barroso et al., 2015).
MR-biosensors have shown promising characteristics, such as, high
sensitivity, fast performance, ﬂexibility, electronic platform compat-
ibility, integrability, miniaturization, scalability and portability
(Martins et al., 2005, 2009, 2010; Germano et al., 2009; Freitas
et al., 2012, 2016; Fernandes et al., 2014). MR-biosensors were able
to detect low concentrations of DNA samples and bacterial cells
(Martins et al., 2009; Fernandes et al., 2014). A femtomolar LOD
was obtained by testing 20 mer ssDNA hybridization events (Martins
et al., 2009) and 3–4 cells of Salmonella Enteritidis per sensor were
detected, by immobilizing bacteriophages on the surface of the MR-
biochip (Fernandes et al., 2014).
Nevertheless, MR-biosensors are prone to systematic artifacts.
These include surface-imposed heterogeneity at the sensor spots (Abs
probe inhomogeneity), diﬀusional eﬀects, avidity, saturation, matrix
eﬀects and non-speciﬁc binding (Morton and Myszka, 1998; Myszka,
1999; Zhang et al., 2006; Martins et al., 2009, 2012; Barroso et al.,
2015). These can be minimized by improving: i) biochip platform
processing hardware (Germano et al., 2009); ii) experimental methods
(Martins et al., 2009; Barroso et al., 2015); and iii) data processing
(Myszka, 1999).
Myszka provides detailed information on minimizing systematic
errors in biochip measurements (Myszka, 1999). For MR-biosensors,
the following can be highlighted:
1. Biochip design and operation variables: i) homogeneity of immobi-
lized Abs; and ii) sample ﬂow and washing. Non-homogeneous
distribution of immobilized Abs decreases reproducibility between
diﬀerent biochips, because the number of binding sites is not
constant. Binding sites saturation sets the maximum concentration
that the biochip can measure, which can be managed by changing
the sample ﬂow and time for binding reaction. However, in practice,
constant ﬂow rates and reaction times are established for allowing
measurement of a range of cell concentrations and the removal of
unbound material on the biochip surface, ensuring eﬃcient and
repeatable procedures (Martins et al., 2012; Barroso et al., 2015).
2. Experimental design: i) reagents and nanoparticles quality; ii)
speciﬁcity; iii) concentration and washing; iv) avidity; and v)
oriented immobilization. For example, washing buﬀers character-
istics (pH, concentration, salinity), type of Abs (speciﬁcity), concen-
Fig. 1. MR-biochip: a) schematic explanation of the sandwich-immunoassay reactions; b) corresponding average voltage variation curves over time, in the right area of the sensors; (A)
baseline - negative MR signal (no label), (B) voltage drop - positive MR signal (MNP@Abs@BCG in contact with the MR-biochip surface), and (C) washing steps - positive MR signal
(MNP@Abs@BCG binded to speciﬁc Abs on the biochip surface).
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tration of Abs and bacteria, and type of surface immobilization
linker, are crucial to the success of MR detection (Martins et al.,
2009, 2010; Barroso et al., 2015).
3. Data processing for artifacts removal: i) baseline correction; ii)
multiplicative eﬀects; iii) replication for determining bias and
precision, as well as, removing white noise. Biochips present poor
baseline reproducibility due to manufacturing limitations. Many
authors recommend 'zeroing', that is, standardizing the voltage
signal in each sensor by subtracting the ﬁrst baseline values to the
biochip signal (Myszka, 1999). This is not enough when the signal
has multiplicative eﬀects due to biochip design and distribution of
immobilized antibodies. Other authors apply normalization for
comparing signals with diﬀerent baselines (Martins et al., 2009;
Fernandes et al., 2014; Barroso et al., 2015), which is also not very
eﬀective in removing systematic artifacts.
The main goal of this study is to provide a proof-of-concept MR-
biosensor for TB POC diagnosis. This research aims to: i) develop a
robust pre-processing technique for eﬀectively removing systematic
eﬀects on the voltage signal; ii) study the eﬀectiveness of chemo-
metrics, for providing an automatic quantiﬁcation method; and iii)
investigate how LOD is aﬀected by these diﬀerent approaches.
2. Materials and methods
2.1. Reagents
Ultrapure water and analytical grade reagents were used in all the
experiments. The reagents for buﬀer preparation were purchased from
Sigma: phosphate buﬀer (PB; 100 mM NaH2PO4, 100 mM Na2HPO4,
pH 7.4), TE buﬀer (10 mM Tris-HCl, 1 mM EDTA, pH 7.4), and bovine
serum albumin (BSA, 1% w/v in TE). Sulfo-LC-SPDP (sulfosuccinimi-
dyl 6-[3′-(2-pyridyldithio)propionamido] hexanoate), the linker for
surface immobilization, was acquired from Pierce. 250 nm Micromod
nanomag®-D magnetic particles have a magnetite core and a dextran
shell, are available in a 4.9 × 1011 particles/mL concentration, and with
a surface modiﬁed with streptavidin, which is suitable for streptavidin-
biotin functionalization with biotinylated antibodies.
2.2. Bacterial strain and polyclonal antibodies
Biosafety Level 3 facilities are required in Mtb bacteria manipula-
tion. Therefore, an attenuated strain used as a vaccine against TB was
applied as a safe surrogate for Mtb: Mycobacterium bovis Bacillus
Calmette-Guérin (BCG) Pasteur from the Trudeau Institute Culture
Collection. BCG samples were grown to mid–log phase in Proskauer-
Beck medium with 0.05% Tween 80 and frozen at −70 °C (Cruz et al.,
2010). Then, a loopful of BCG resuspended in PB buﬀer was treated as
described by Bettencourt and co-workers to obtain 1 × 107 bacteria per
mL, at an optical density of 600 nm (Bettencourt et al., 2010).
Polyclonal antibodies (Abs), from Thermo Fisher Scientiﬁc, biotin
conjugated anti-M. tuberculosis (anti-Mtb bio, PA1-73136, 4–5 mg/
mL), anti-M. tuberculosis (anti-Mtb, PA1-7260, 4–5 mg/mL) and anti-
Salmonella (anti-Salm, PA1-20811, 1 mg/mL), were washed from their
preservative solution by ﬁltering with Millipore centrifugal ﬁlters
(100 kDa cut-oﬀ, 10.000 rpm, 15 min) and exchanged to PB buﬀer to
the desired concentration. The Abs concentration was optimized in
previous studies (Barroso et al., 2015).
2.3. Bioconjugation of MNP with anti-Mtb bio and BCG
Streptavidin capped MNP, with a 106 NP/μL concentration, were
magnetically washed 3 times with PB, using a magnetic concentrator
(Dynal-biotech), and then allowed to react with 25 μg/mL of anti-Mtb
bio, in a total volume of 200 μL. This solution was incubated 1 h, at
200 rpm and room temperature (RT). After Abs immobilization on the
MNP, free reactive sites on MNP surface were blocked with BSA in TE
for 30 min, at 200 rpm and RT, to avoid non-speciﬁc adsorption of
other proteins or false positive results. Then, functionalized MNP were
magnetically washed 3 times with PB. The magnetic capture of BCG
was performed by incubating 200 μL of diﬀerent concentrations of BCG
cells (0/104/105/106/107 cells/mL) with MNP@Abs, for 1 h, at
200 rpm and RT, resulting in MNP@Abs@BCG detection probes.
Then, each concentration level was magnetically washed 3 times with
PB and re-suspended in PB until further use.
Optimization studies, regarding the eﬃciency of the magnetic
capture and further recognition of BCG bacteria by capture Abs on
the MR-biochip surface, were conducted in a previous work (Barroso
et al., 2015).
2.4. Bioconjugated MNP immobilization on the MR-biochip
The MR-biochip was developed by INESC MN and the probe
immobilization surface consists of patterned Cr/Au pads, with MR
sensors beneath. Basically, the MR-biochip includes two separate gold
sensing areas, each one with 3 groups of 5 U-shaped 2.5 × 80 µm2 spin-
valve sensors, in a total of 30 active testing sensors (Martins et al.,
2009). After rigorous cleaning of the surface to remove the protective
resist layer and residues, a droplet of 20 μL of sulfo-LC-SPDP, a
heterobifunctional cross-linker for immobilization with amino groups,
was placed over the surface for 1 h, at RT, in a humidiﬁed atmosphere
(HA) (Fernandes et al., 2014). The surface was then rinsed with PB and
ultrapure water, and gently dried with a nitrogen gun. Then, droplets of
1 μL of both negative control (anti-Salm) and positive sample (anti-
Mtb), both with a 50 μg/mL concentration, were manually spotted on
the surface, respectively on the left and right sides, and incubated for
2 h, at RT, in HA. To remove unbound Abs and block nonspeciﬁc
adsorption, the gold surface was rinsed with PB, and 20 μL of BSA in
TE were allowed to react 1 h, at RT, in HA. Finally, the surface was
rinsed with PB to remove the excess of blocking solution.
2.5. MR-biochip measurement
The MR-biochip is a plugged-in electronic platform (Germano
et al., 2009). The device has a microﬂuidic channel controlled by a
syringe pump (New Era NE-300) that controls and loads the sample
into the MR-biochip. Measurements were performed with 1 mA biasing
current for the sensors, and an external 3 mT magnetic bias ﬁeld and
1.35 mT rms AC ﬁeld for magnetizing the MNP. The baseline signal
acquisition was provided by 15 min of PB buﬀer ﬂow. Then, 5 μL of
MNP@Abs@BCG in PB were introduced and settle down on the surface
of the sensor for 30 min. Finally, two washing steps with PB buﬀer
allowed the removal of unbound MNP, ﬁrst at a ﬂow rate of 5 μL/min
for 5 min, and then 50 μL/min for 5 min. All throughout this process,
the signal acquisition was sequentially measured for all sensors inside
the MR-biochip. The ΔVbinding in each sensor was obtained by the
voltage diﬀerential between the baseline signal (Vsensor) and the
binding signal in the 50 μL/min washing step (Vparticles): ΔVbinding =
Vsensor-Vparticles. This diﬀerential is proportional to the number of
magnetically labelled mycobacteria, successfully bound to the surface.
The ΔVbinding is then normalized to each sensor baseline signal (Vsensor)
at the measurement conditions (ΔVbinding /Vsensor), to compare diﬀer-
ent sensors in the same assay and among diﬀerent MR-biochips
(Martins et al., 2009).
2.6. Data processing
2.6.1. Biochip speciﬁcity
Biochip speciﬁcity (binding aﬃnity) was tested by comparing the
signal intensities between positive and negative sensors, at diﬀerent
BCG bacteria concentrations (ﬁve levels: 0/104/105/106/107 cells/mL).
Student's t-test was performed to determine signal diﬀerences at each
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level. Fisher's test (F-test) was performed to evaluate tendency between
variance of positive and negative signals (Knuter et al., 2005).
2.6.2. Multiplicative signal correction
Multiplicative signal correction (MSC) was used to correct baseline
and proportional systematic eﬀects (Martens and Stark, 1991; Martens
et al., 2003; Gallagher et al., 2005). Both eﬀects can be corrected by:
VV = βcor
Where Vcor is the corrected voltage, V is the recorded voltage and β are
the correction coeﬃcients calculated by minimizing the distance to a
reference voltage proﬁle (dJ).
d β V β V= + −J j ref1 2
Where dj is the distance, Vj is the voltage proﬁle of sample j and Vref is
the mean reference voltage proﬁle. Once the error is minimized, V is
corrected into Vcor, without the eﬀects of diﬀerent baselines and
proportional systematic multiplicative eﬀects. Vcor is afterwards used
in the calibration curves. For any new biochip TB measurement, the
correction is applied before quantiﬁcation, using the recorded mean
reference voltage proﬁle.
2.6.3. Biochip linear calibration
Biochip calibration is the process of ﬁnding a relevant statistical
relationship between MR voltage and cell concentration.
Magnetoresistance increases non-linearly with BCG cell concentration
(CTB). A log-linear function is observed: log10 (CTB) = f (ΔVbinding/
Vsensor).
Linear regression was performed using the least-squares optimiza-
tion method. Regression coeﬃcients were analyzed for statistical
signiﬁcance using the t-student statistics, and linearity was assessed
by analysis of variance (ANOVA) for determining the p-value of the
linear relationship (Knuter et al., 2005). The LOD was considered 10
fold of the regression standard error.
The standard deviation (SD) and coeﬃcient of variation (CV) of the
voltage drop (ΔVbinding/Vsensor), for each MR-biosensor at diﬀerent
BCG cell concentrations were calculated, determining the reproduci-
bility of the biochips at each level. Bias was calculated as the diﬀerence
from the linear model prediction and the actual concentration value.
2.6.4. Principal component regression
Principal component regression (PCR) is a multivariate calibration
that uses the biochip voltage proﬁle to establish a linear relationship
between cell concentration and projection of scores into the principal
components. PCR relates the orthogonally decomposed variance in the
voltage signal proﬁle with the cell concentration. The inclusion of more
than one relevant principal component in the PCR regression denotes
non-random variation in the voltage signal, which contains information
about cell concentration. Once more systematic information is avail-
able to relate cell concentration, less bias and variance is expected in
the MR-biochip calibration (Hastie et al., 2009).
2.6.5. Partial least-squares regression
Partial least-squares regression (PLS) maximizes the co-variance
between biochip voltage (V) and cell concentration (C); and their
corresponding latent variables (LV). In PLS, the co-variance matrix is
orthogonally decomposed so that it maximizes each LV correlation.
PLS coeﬃcients are obtained using only the latent dimensions that are
able to represent information of projection of C in V. The optimized
coeﬃcients are obtained at the number of LV that minimizes the cross-
validation prediction error sum of squares (Lindgren et al., 1993; Wold
et al., 2001; Trygg and Wold, 2002).
2.6.6. Validation
All models (linear regression, PCR and PLS) were obtained using
cross-validation with the "leave-one-out" methodology. The standard
error (SE) was obtained by summing the prediction error of each
sample that was left out of the training batch (Knuter et al., 2005). The
number of LV, in both PCR and PLS, was determined by minimizing
the mean prediction square error, obtaining a stable multivariate
model that correctly balances bias vs. variance (Sutter et al., 1992;
Wentzell and Montoto, 2003; Hastie et al., 2009). Model coeﬃcients
variance and t-test were obtained by bootstrapping and re-sampling
(Manly, 1998; Knuter et al., 2005). The coeﬃcient of determination (R-
adj) and Pearson correlation (R2) were used as metrics of tendency.
The p-value of all models was assessed by the F-test between measured
and predicted values (Knuter et al., 2005). All statistical models were
performed using R (R-project, 2017).
3. Results and discussion
3.1. Biochip speciﬁcity
Despite the fact that anti-Salm Abs showed some unspeciﬁc binding
events, the signal obtained in the positive sensors (anti-Mtb) was
always higher and statistically diﬀerent from the signal coming from
the negative control sensors (anti-Salm).
Fig. 2 presents the MR signal intensities after washing, for anti-Mtb
positive sample and anti-Salm negative control, at diﬀerent concentra-
tions of BCG cells (104 to 107 cells/mL), as well as, the zero level signal
(0 cells/mL). The MR signals of anti-Mtb positive samples are higher
than the zero level signals, for all cell concentrations. The anti-Salm
negative sensors always present lower MR signals (ΔVbinding), for any
cell concentration, than the positive anti-Mtb sensors. Even at the
lowest concentration (104 cells/mL), the voltage diﬀerential (ΔVbinding/
Vsensor) of negative controls is signiﬁcantly lower than the positive
samples (p < 10−3). All positive samples have signiﬁcantly higher values
than both zero level signal and negative control (p < 10−3). In both
negative controls and positive samples, the signal intensity increases
with concentration, as well as, the diﬀerence between control and
sample signals.
The MR signal in positive samples is always higher than in negative
controls (p < 10−3). Nevertheless, total speciﬁcity is apparently not
achieved. The negative signal increases with BCG concentration, which
is a sign of non-speciﬁc binding between anti-Salm control Abs and
BCG bacteria. This non-speciﬁc binding is linearly correlated to BCG
concentration, and therefore, it is a systematic limitation of the MR-
biochip, not aﬀecting performance, since the proportion is maintained
across the diﬀerent replicates. There is a direct linear relationship
between the signal increase of negative control and positive samples (p
< 0.05). Such is a good indication that non-speciﬁc binding is linearly
Fig. 2. Biochip speciﬁcity in raw data: diﬀerences between signal intensities of anti-Mtb
positive samples and anti-Salm negative controls (black - positive sample; yellow -
negative control; red - maximum background from 0 cells/mL).
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related to BCG concentration, and should not aﬀect the quality of TB
quantiﬁcation. This eﬀect has been already observed in previous
studies (Martins et al., 2009; Barroso et al., 2015).
3.2. Multiplicative signal correction
Fig. 3 shows how MSC improves the original MR-biochip signal.
Fig. 3a shows raw data and Fig. 3b presents data after MSC.
The raw data indicates that the initial baseline is not the same for
the diﬀerent sensors and replicates. For each cell concentration, the
baseline variance is signiﬁcant, with an average CV of 6.1% (Table 1).
The same is observed after washing, where the signal has an average
CV of 6.1%. This variation masks the direct comparison of the voltage
proﬁle at diﬀerent cell concentrations (Fig. 3a).
After MSC, the MR signal at diﬀerent concentration levels is clearly
visible (Fig. 3b). All baselines are corrected to a similar value with an
average of 4489.74 µV, and extremely low variance (average
CV 0.11%). Moreover, the voltage in washing decreases with BCG cell
concentration levels, which was not directly observable in the original
signal, because systematic eﬀects were uncorrected. Also, the voltage in
washing reaches low variance (average CV 0.4%, see Table 1). MSC on
MR-biochip proves to be extremely eﬀective. The voltage signal, both in
baseline and washing, is corrected and maintains proportionality to
BCG cell concentration. The corrected voltage proﬁle is now distin-
guishable for diﬀerent cell concentrations, which is an indication that
MSC preserves the information about diﬀerential eﬀects and binding
reactions at the MR-biochip surface.
Results show that the voltage potential (ΔVbinding) increases linearly
with the decimal logarithm of cell concentration: log10(cell/mL) =
f(ΔV). The direct calibration using the normalized raw data has a
standardize error (SE) of 0.5 log10(cells/mL) and r
2 = 0.8145 (p <
10−9). Quantiﬁcation using the direct voltage had signiﬁcant error,
because systematic errors were left uncorrected. An SE of 0.5 is only
satisfactory for providing qualitative TB data classiﬁcation, for exam-
ple, the CV of the baseline or washing was around 10%, which
inevitably led to high dispersion in the direct calibration curve
(Table 1). Once the original signal has been corrected by MSC, SE
drops to 0.03309 (r2 = 0.95562). Such is a very signiﬁcant improve-
ment, as the CV at 104 cells/mL is now only 8.27%, providing data with
quantiﬁcation capacity within 104 to 107 cells/mL.
The eﬀect of MSC is also directly visible in Fig. 4a. This strategy
signiﬁcantly reduces the variance dispersion of the voltage drop in
washing, when compared to non-MSC correction, as presented in the
raw data of Fig. 2.
3.3. Principal component regression and Partial least-squares
regression
MSC has the same eﬀect on the PCR model. Raw data only allows to
obtain a PCR model with high variance (SE = 0.5325; r2 = 0.8229, LV =
1), whereas, MSC allows a PCR model with well-balanced bias-variance
(SE = 0.1245, r2 = 0.9924, LV = 2). Such is a signiﬁcant improvement
against the zeroing or normalization methods. With an extremely low
MAPE at the lower concentration (3.11%), the MR-biochip can now
reach analytical quality in TB quantiﬁcation from 104 to 107 cell/mL
(ISO, 2006; Westgard, 2015). In Table 2 is possible to observe that the
SE of PCR calibration is 0.1245, a very signiﬁcant decrease when
compared with the traditional normalization or non-MSC corrected
signal (SE~0.5).
PLS achieves better results, obtaining analytical quality calibration
curve with r2 = 0.9943 and MAPE < 1% (Table 2). PLS outperforms
PCR, because it maximizes co-variance between cell concentration and
voltage signal, extracting the regression coeﬃcients that linearity relate
the voltage curve pattern to cell concentration.
Fig. 3. Voltage mean signal correction: a) raw biochip voltage curves; b) corrected biochip voltage curves.
Table 1
Voltage variation of the magnetoresistive biochip.
Concentration (cells/mL) Original Signal (µV) Corrected Signal (µV)
Baseline Washing Baseline Washing
104 3342.99 ± 305.45 3338.95 ± 303.86 4497.20 ± 5.34 4491.74 ± 7.13
105 3783.22 ± 248.29 3750.38 ± 243.89 4486.26 ± 3.79 4447.43 ± 5.62
106 5103.12 ± 347.89 4915.04 ± 342.16 4481.51 ± 6.12 4311.45 ± 11.07
107 5072.98 ± 102.27 4783.95 ± 89.61 4493.97 ± 5.32 4228.09 ± 45.11
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These results suggest that the voltage curve has signiﬁcant informa-
tion that can be used to quantify BCG cells. Even after MSC correction,
using a linear model of the voltage drop in washing, the SE is 0.3309,
which is ten times greater than the PLS approach. These results allow
concluding that the main variance of voltage proﬁle contains systematic
information about BCG concentration and should be explored in MR-
biochip technology to obtain better quantitative models.
Furthermore, the calculation of ΔVbinding/Vsensor introduces var-
iance. As the voltage proﬁle in washing is also dependent on diﬀusion
and ﬂuid ﬂow, the voltage diﬀerence between baseline and washing is
not totally reproducible, even after MSC correction.
Because the dynamics of diﬀusion and reaction are recorded in the
voltage proﬁle, the MR-biochip fabrication and sample preparation
should be kept reproducible, so that chemometrics methodology is
eﬀective in MR-biochips, as we suggest in Fig. 4b:
– Calibration step: i) perform measurements with MR-biochips from
diﬀerent production lots, and register the voltage proﬁles for
diﬀerent concentrations; ii) perform MSC to all voltage proﬁles
and register the reference voltage proﬁle; and iii) build the calibra-
tion model;
– Prediction step for unknown samples: i) record the voltage proﬁle
for an unknown sample; ii) correct the signal with MSC using the
reference voltage proﬁle; and iii) predict the BCG concentration
using the calibration model.
3.4. Calibration and detection limit
The LOD allows us to explore the limits of the MR-biochip
technology for TB diagnosis. The SE of MSC-PCR and MSC-PLS
calibrations allow LOD of 13.3 cell/mL and 10.8 cell/mL, respectively.
Such low LOD allows the extrapolation that the MR-biochip is able to
measure BCG bellow 104 cells/mL, without compromising the analy-
tical quality of the quantiﬁcation. This was the initial objective of the
study, because ZN can go as low as 104 cells/mL.
Although calibration results show very low SE, the MR-biochip
needs to improve: i) functionalization protocol; and ii) non-speciﬁc
binding. The current MNP@Abs@BCG functionalization protocol in-
volves too many manual steps of magnetic separation and washing. In
each step there is a small loss of MNP, which at the end of the
bioconjugation, contributes to a slightly diﬀerent content of MNP in
each level of BCG concentration. This variation introduces systematic
errors in the measurement, reducing the reproducibility of the method.
Furthermore, diﬀerent MR-biochip fabrication batches will always
present small diﬀerences. Most of the biochip signal variability arises
from: i) MNP interference; ii) Abs density and distribution on the
biochip surface; iii) electronics fabrication; and iv) diﬀusional eﬀects
on the biochip surface. Also, systematic eﬀects from the MR-biochip
fabrication (e.g. biochip area and MR sensitivity), result in the observed
voltage curves in Fig. 3a, in cell concentration levels from 104 to 107
cells/mL. Ideally, the baseline signal should be identical for every MR-
biochip measurement, and the voltage drop should be similar for the
same cell concentration.
Procedures to decrease non-speciﬁc binding, as well as, decreasing
the deposition of cells at the sensor surface area with no antibody-
antigen immobilization, by increasing the washing steps and improving
washing buﬀers eﬃcacy, would be recommended for better eﬃciency
and reproducibility. Moreover, speciﬁc interference tests, cross-reac-
tivity tests, as well as, automatizing the magnetic separation and
washing steps during functionalization should greatly reduce systema-
Fig. 4. a) Signal intensities of anti-Mtb positive samples after MSC data treatment (black - positive sample; red - maximum background from 0 cells/mL); b) schematic explanation of
the biochip multivariate chemometrics method.
Table 2
Biochip calibration results.
Model Data Type SEa R2b p-valuec
Linear I Raw normalized voltage Linear least squares regression 0.5046 0.8145 < 1 × 10−9
Linear II Corrected voltage Linear least squares regression 0.3309 0.9562 < 1 × 10−9
PCR I Raw normalized voltage Principal component regression 0.5325 0.8229 < 1 × 10−9
PCR II Corrected voltage Principal component regression 0.1245 0.9924 < 1 × 10–16
PLS I Corrected voltage Partial least squares 0.0322 0.9993 < 1 × 10–16
a Standard Error: blind tests error.
b Regression correlation coeﬃcient.
c Fisher's test p-value.
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tic errors. Also, random sampling tests could be done, using process
analytical techniques, such as multi-variate control charts, which can
be implemented for controlling the quality of diﬀerent MR-biochips
batches (Mitsutake et al., 2015).
3.5. Benchmark with the state-of-the-art
The benchmark LOD on biosensors for TB diagnosis is currently 8 ×
102 cells/mL, obtained with an electrochemical biosensor based in a
microtip immunoassay for H37Ra cells (Yeo et al., 2010). Electronic
nose technology achieved a LOD of 104 in RIVM myc 4514 cells (Fend
et al., 2006). Mechanical biosensors in attenuated Mtb cells achieved
LOD of 2 × 103 (He et al., 2003) and 105 (He and Zhang, 2002),
respectively, with acoustic wave and quartz crystal microbalance. In
optical biochips, LOD was 103 and 104 cells/mL with Mtb sputum
samples, respectively, when using isothermal loop mediated ampliﬁca-
tion (Creecy et al., 2015) and capture ELISA of lipoarabinomannan
antigen (Arias-Bouda et al., 2000). Similar LOD results, 103 and 104,
were achieved by magnetic methods, respectively, by using a magnetic
barcode in sputum (Liong et al., 2013) and a magnetoelastic biosensor
in Mtb H37Ra strain cells (Pang et al., 2008).
The SE obtained by PCR and PLS models (Table 2) allows concluding
that the MR-biochip technology is a potential candidate to replace ZN in
POC context. If one considers that the LOD is 10% the SE, we deduce
that the estimated LOD can achieve 10.8 cells/mL in the PLS model and
13.3 cells/mL in the PCR model, which is below 104 cells/mL.
4. Conclusions
This research presents a proof-of-concept POC MR-biosensor plat-
form for TB diagnosis. Results show that, although the binding of BCG
is not 100% speciﬁc, the diﬀerence of the MR voltages between positive
sample and negative control or zero level background is always
statistically signiﬁcant.
Results also demonstrate that systematic artifacts, due to hardware
limitations in MR-biochips, are eﬀectively corrected using MSC tech-
niques. Furthermore, when MSC is coupled with chemometrics model-
ling (PCR and PLS), signiﬁcant reproducibility and LOD gains are
obtained. Therefore, we propose the implementation of an algorithm to
be used in the MR-biosensor technology.
In conclusion, the low LOD of the MR-biosensor presents high
potential for TB diagnosis at the point-of-care. However, MR-biochip
technology still relies on pre-processing of samples before measure-
ments. Future research on the extraction and isolation procedures of
clinical samples will allow the use of the presented technology in real
world applications.
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